CARDIOVASCULAR RNA MARKERS AND ARTIFICIAL INTELLIGENCE MAY IMPROVE COVID-19 OUTCOME : POSITION PAPER FROM THE EU-CardioRNA COST Action CA17129
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Robinson, Emma L. (Maastricht University)
Jusic, Amela (Cardiovascular Research Unit)
Carpusca, Irina (Cardiovascular Research Unit)
de Windt, Leon J.. (Department of Molecular Genetics)
Emanueli, Costanza (National Heart & Lung Institute)
Ferdinandy, Péter (Cardiometabolic Research Group and MTA-SE System Pharmacology Research Group)
Gu, Wei (Luxembourg Center for Systems Biomedicine)
Gyöngyösi, Mariann (Department of Cardiology)
Hackl, Matthias (TAmiRNA GmbH)
Karaduzovic-Hadziabdic, Kanita (Faculty of Engineering and Natural Sciences)
Lustrek, Mitja (Department of Intelligent Systems)
Martelli, Fabio (Molecular Cardiology Laboratory)
Nham, Eric (University of Zagreb School of Medicine)
Potočnjak, Ines (Institute for Clinical Medical Research and Education)
Satagopam, Venkata (Luxembourg Center for Systems Biomedicine)
Schneider, Reinhard (Luxembourg Center for Systems Biomedicine)
Thum, Thomas (Institute of Molecular and Translational Therapeutic Strategies (IMTTS))
Devaux, Yvan (Cardiovascular Research Unit)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of February 8th, 2020 and causing more than 2. 3 million deaths according the World Health Organization. Not only affecting the lungs and provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Hence a significant proportion of infected patients develop cardiac events such as arrhythmias and heart failure. Patients with cardiovascular comorbidities are at highest risk of cardiac death. To face the pandemic and limit its burden, health authorities have launched several fast track calls for research projects aiming to develop rapid strategies to combat the disease, as well as longer-term projects to prepare for the future. Biomarkers have the possibility to aid in clinical decision making and tailoring healthcare in order to improve patient quality of life. The biomarker potential of circulating RNAs has been recognized in several disease conditions, including cardiovascular disease. RNA biomarkers may be useful in the current COVID-19 situation. The discovery, validation and marketing of novel biomarkers, including RNA biomarkers, require multi-centre studies by large and interdisciplinary collaborative networks, involving both the academia and the industry. Here, members of the EU-CardioRNA COST Action CA17129 summarize the current knowledge about the strain that COVID-19 places on the cardiovascular system and discuss how RNA biomarkers can aid to limit this burden. They present the benefits and challenges of the discovery of novel RNA biomarkers, the need for networking efforts and the added value of artificial intelligence to achieve reliable advances.
Grants:	European Commission 101016072
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Biomarkers ; Artificial intelligence ; RNAs ; Genomics
Published in:	Cardiovascular research, april 2021, ISSN 1755-3245

DOI: 10.1093/cvr/cvab094
PMID: 33839767

50 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles